AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19751560 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment without low-dose hydrocortisone)
Number of subjects: 77
Study 17299470 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of oral riboflavin and other B-group vitamins daily for 14 days
Number of subjects: 96
Study 17299470 — intervention group
Group type: COMPARATOR
Intervention: No B-vitamins for 14 days (Control group)
Number of subjects: 96
Study 15496622 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy
Number of subjects: 421
Study 15496622 — intervention group
Group type: COMPARATOR
Intervention: Postoperative chemoradiotherapy
Number of subjects: 421
Study 11486924 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual presentation of words
Number of subjects: 0
Study 11486924 — intervention group
Group type: COMPARATOR
Intervention: Aural presentation of words
Number of subjects: 0
Study 11486924 — intervention group
Group type: EXPERIMENTAL
Intervention: Spoken recall mode
Number of subjects: 0
Study 11486924 — intervention group
Group type: EXPERIMENTAL
Intervention: Orienting task with aural presentation
Number of subjects: 0
Study 9934234 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized simulations
Number of subjects: 38
Study 9934234 — intervention group
Group type: COMPARATOR
Intervention: Traditional seminars
Number of subjects: 38
Study 7923916 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX)
Number of subjects: 0
Study 7923916 — intervention group
Group type: COMPARATOR
Intervention: Control (age-matched controls)
Number of subjects: 0
Study 2839538 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg iv bolus dose of methoxamine
Number of subjects: 0
Study 2839538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30457655 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly ranibizumab dosing
Number of subjects: 20
Study 30457655 — intervention group
Group type: COMPARATOR
Intervention: Treat-and-extend (T&E) ranibizumab dosing
Number of subjects: 20
Study 28657367 — intervention group
Group type: COMPARATOR
Intervention: 0.25 mm nanotips
Number of subjects: 16
Study 28657367 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mm nanotips
Number of subjects: 16
Study 28657367 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mm traditional micro-needles
Number of subjects: 16
Study 28657367 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mm traditional micro-needles
Number of subjects: 16
Study 25764996 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment for 1 year in infants (m/f: 11/8)
Number of subjects: 47
Study 25764996 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment for 2 years in prepubertal children (m/f: 14/14)
Number of subjects: 47
Study 25764996 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 47
Study 24092509 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/remifentanil intravenous anaesthesia
Number of subjects: 83
Study 24092509 — intervention group
Group type: COMPARATOR
Intervention: Desflurane/fentanyl general anaesthesia
Number of subjects: 83
Study 24092509 — intervention group
Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 83
Study 24092509 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/remifentanil
Number of subjects: 83
Study 21045734 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment with amlodipine/valsartan 10/320 mg (after dose increase at week 2) and hydrochlorothiazide 12.5 mg (added at week 4)
Number of subjects: 728
Study 21045734 — intervention group
Group type: COMPARATOR
Intervention: Moderate treatment with amlodipine/valsartan 5/160 mg and hydrochlorothiazide 12.5 mg (added at week 4)
Number of subjects: 728
Study 21045734 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment with amlodipine/valsartan 10/320 mg and hydrochlorothiazide 12.5 mg
Number of subjects: 728
Study 21045734 — intervention group
Group type: COMPARATOR
Intervention: Moderate treatment with amlodipine/valsartan 5/160 mg and hydrochlorothiazide 12.5 mg
Number of subjects: 728
Study 18565008 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care intervention based on the chronic care model, including patient and provider activation and education, patient assessment, outcomes monitoring, and feedback to providers over 12 months.
Number of subjects: 401
Study 16873425 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line capecitabine, second-line irinotecan, third-line capecitabine + oxaliplatin (arm A)
Number of subjects: 820
Study 16873425 — intervention group
Group type: COMPARATOR
Intervention: First-line capecitabine + irinotecan, second-line capecitabine + oxaliplatin (arm B)
Number of subjects: 820
Study 12973957 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoprecipitate (5 units)
Number of subjects: 17
Study 12973957 — intervention group
Group type: COMPARATOR
Intervention: Fresh Frozen Plasma (FFP, 4 units)
Number of subjects: 17
Study 10900813 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental leaders led to believe their trainees had higher than usual potential
Number of subjects: 0
Study 10900813 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 8695601 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysaccharide-free diet with breakfast supplement (biscuits made from wheat, potato, or banana flours; moist-heat-processed wheat or maize flours)
Number of subjects: 9
Study 1290920 — intervention group
Group type: EXPERIMENTAL
Intervention: terazosin
Number of subjects: 17
Study 1290920 — intervention group
Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 17
Study 6386028 — intervention group
Group type: EXPERIMENTAL
Intervention: SHRZ6 regimen (6 months of isoniazid and rifampicin supplemented for the first 2 months by streptomycin and pyrazinamide)
Number of subjects: 444
Study 6386028 — intervention group
Group type: EXPERIMENTAL
Intervention: EHRZ6 regimen (6 months of isoniazid and rifampicin supplemented for the first 2 months by ethambutol and pyrazinamide)
Number of subjects: 444
Study 6386028 — intervention group
Group type: COMPARATOR
Intervention: EHR9 regimen (9 months of isoniazid and rifampicin supplemented for the first 2 months by ethambutol)
Number of subjects: 444
Study 30144084 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic sensitization at the time of the first wheezing episode
Number of subjects: 76
Study 30144084 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial reactivity after exercise challenge or bronchodilation
Number of subjects: 76
Study 28481823 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH online education modules
Number of subjects: 26
Study 28481823 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity (PA)
Number of subjects: 26
Study 26825826 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic radical hysterectomy (RRH) plus pelvic lymphadenectomy
Number of subjects: 41
Study 26825826 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic radical hysterectomy plus pelvic lymphadenectomy
Number of subjects: 41
Study 26825826 — intervention group
Group type: COMPARATOR
Intervention: Abdominal radical hysterectomy plus pelvic lymphadenectomy
Number of subjects: 41
Study 23128847 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (AT) 3x a week at individual anaerobic threshold
Number of subjects: 71
Study 23128847 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyostimulation (EMS) 10 Hz, 20s 'on'/20s 'off', applied to leg extensors for 2 h/day
Number of subjects: 71
Study 23128847 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of AT and EMS (AT+EMS)
Number of subjects: 71
Study 22320418 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%/timolol maleate 0.5% fixed combination (LTFC)
Number of subjects: 33
Study 22320418 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide hydrochloride 2%/timolol maleate 0.5% fixed combination (DTFC)
Number of subjects: 33
Study 21145518 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching treatment performed by physical therapists
Number of subjects: 20
Study 21145518 — intervention group
Group type: COMPARATOR
Intervention: Stretching treatment performed by parents
Number of subjects: 20
Study 17420419 — intervention group
Group type: COMPARATOR
Intervention: Cocoa products (median duration 2 weeks)
Number of subjects: 516
Study 17420419 — intervention group
Group type: COMPARATOR
Intervention: Black and green tea (median duration 4 weeks)
Number of subjects: 516
Study 15640320 — intervention group
Group type: EXPERIMENTAL
Intervention: CRQ-Self-Administered (CRQ-SA)
Number of subjects: 177
Study 15640320 — intervention group
Group type: COMPARATOR
Intervention: CRQ-Interviewer Administered (CRQ-IA)
Number of subjects: 177
Study 15640320 — intervention group
Group type: COMPARATOR
Intervention: Standardised dyspnoea domain
Number of subjects: 177
Study 15640320 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised dyspnoea domain
Number of subjects: 177
Study 17823666 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-based mouthrinse
Number of subjects: 20
Study 17823666 — intervention group
Group type: COMPARATOR
Intervention: Nonalcohol-based mouthrinse
Number of subjects: 20
Study 10867767 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transmyocardial laser revascularization (PTMR)
Number of subjects: 550
Study 10867767 — intervention group
Group type: COMPARATOR
Intervention: Best medical therapy
Number of subjects: 550
Study 8792352 — intervention group
Group type: EXPERIMENTAL
Intervention: Opsite 3000TM (transparent moisture vapor permeable dressings, MVPD) changed weekly
Number of subjects: 101
Study 8792352 — intervention group
Group type: COMPARATOR
Intervention: Dry, sterile gauze dressing (DSGD) changed every 24 hours
Number of subjects: 101
Study 1480726 — intervention group
Group type: EXPERIMENTAL
Intervention: structured and modularized skills training
Number of subjects: 41
Study 1480726 — intervention group
Group type: COMPARATOR
Intervention: supportive group psychotherapy
Number of subjects: 41
Study 1480726 — intervention group
Group type: EXPERIMENTAL
Intervention: skills training
Number of subjects: 41
Study 6734061 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulant group (allowed to be fully ambulant)
Number of subjects: 200
Study 6734061 — intervention group
Group type: COMPARATOR
Intervention: Bed rest group (confined to bed for 24 h)
Number of subjects: 200
Study 31586879 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination with controlled ovarian hyperstimulation (IUI‐COH)
Number of subjects: 333
Study 31586879 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified natural cycle in vitro fertilization (IVF‐MNC)
Number of subjects: 333
Study 31586879 — intervention group
Group type: EXPERIMENTAL
Intervention: Single embryo transfer IVF (IVF‐SET)
Number of subjects: 333
Study 31586879 — intervention group
Group type: COMPARATOR
Intervention: Naturally conceived group
Number of subjects: 333
Study 30282056 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A)
Number of subjects: 0
Study 30282056 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU plus the Youth Outcomes Questionnaire (YOQ)
Number of subjects: 0
Study 30282056 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 27402969 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 2060
Study 24506274 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetic gel (5% lidocaine and 5% prilocaine) applied in the sulcus 5 minutes before the procedure
Number of subjects: 30
Study 24506274 — intervention group
Group type: COMPARATOR
Intervention: Control group (no anesthetic gel)
Number of subjects: 30
Study 22633477 — intervention group
Group type: EXPERIMENTAL
Intervention: R2 sympathicotomy
Number of subjects: 100
Study 22633477 — intervention group
Group type: EXPERIMENTAL
Intervention: R2-R3 sympathicotomy
Number of subjects: 100
Study 20694407 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/day of PUFAs
Number of subjects: 40
Study 20694407 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 18405951 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 200 mcg (for patients aged < 11 years) or 400 mcg once daily
Number of subjects: 7241
Study 18405951 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus usual asthma therapy
Number of subjects: 7241
Study 18405951 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 7241
Study 15967303 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product (Diphenidol)
Number of subjects: 0
Study 15967303 — intervention group
Group type: COMPARATOR
Intervention: Reference product (Diphenidol)
Number of subjects: 0
Study 12053591 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (two puffs four times daily, 0.002 g/puff)
Number of subjects: 81
Study 12053591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 10609422 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal and social rhythm therapy (IPSRT)
Number of subjects: 82
Study 10609422 — intervention group
Group type: COMPARATOR
Intervention: Intensive clinical management (CM)
Number of subjects: 82
Study 8519669 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary treatment: debulking surgery followed by platinum-based chemotherapy
Number of subjects: 362
Study 8519669 — intervention group
Group type: EXPERIMENTAL
Intervention: Second debulking operation (randomised intervention)
Number of subjects: 362
Study 29972393 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle-sparing thoracotomy (MST)
Number of subjects: 40
Study 29972393 — intervention group
Group type: COMPARATOR
Intervention: Standard posterolateral thoracotomy (PLT)
Number of subjects: 40
Study 27663942 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label Atomoxetine (ATX) + Parent Training (PT)
Number of subjects: 117
Study 27663942 — intervention group
Group type: COMPARATOR
Intervention: Open-label Atomoxetine (ATX) alone
Number of subjects: 117
Study 27663942 — intervention group
Group type: COMPARATOR
Intervention: Placebo nonresponders treated with open-label Atomoxetine (ATX) for 10 weeks
Number of subjects: 117
Study 27663942 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment responders from the acute trial
Number of subjects: 117
Study 24581813 — intervention group
Group type: EXPERIMENTAL
Intervention: Food safety map
Number of subjects: 73
Study 24581813 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooking class
Number of subjects: 73
Study 24581813 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study 22890209 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 28
Study 22890209 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 28
Study 22890209 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy matched controls)
Number of subjects: 28
Study 20664284 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan-based therapy
Number of subjects: 100
Study 20664284 — intervention group
Group type: COMPARATOR
Intervention: CCB-based therapy
Number of subjects: 100
Study 17879428 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest BMI quintile
Number of subjects: 89835
Study 17879428 — intervention group
Group type: COMPARATOR
Intervention: Lowest BMI quintile
Number of subjects: 89835
Study 15180174 — intervention group
Group type: EXPERIMENTAL
Intervention: Sigmasporin Microoral 100 mg
Number of subjects: 24
Study 15180174 — intervention group
Group type: COMPARATOR
Intervention: Sandimmune Neoral 100 mg
Number of subjects: 24
Study 12206354 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional endoscopic sinus surgery (FESS)
Number of subjects: 50
Study 12206354 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 50
Study 11475748 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymatrine 600 mg per day intramuscularly
Number of subjects: 43
Study 11475748 — intervention group
Group type: COMPARATOR
Intervention: General liver protective agents (vitamins)
Number of subjects: 43
Study 7806419 — intervention group
Group type: EXPERIMENTAL
Intervention: Complement activating membranes (cuprophan)
Number of subjects: 0
Study 7806419 — intervention group
Group type: COMPARATOR
Intervention: Non-activating membranes (polysulfone, polymethylmethacrylate, polyacrylonitrile)
Number of subjects: 0
Study 2561379 — intervention group
Group type: EXPERIMENTAL
Intervention: Short‐lasting intensive immunosuppression (cyclophosphamide with ACTH)
Number of subjects: 16
Study 2561379 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular ACTH
Number of subjects: 16
Study 976003 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended mastectomy
Number of subjects: 1580
Study 976003 — intervention group
Group type: COMPARATOR
Intervention: Radical mastectomy
Number of subjects: 1580
Study 30056743 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based vestibular rehabilitation for eight weeks
Number of subjects: 65
Study 30056743 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 65
Study 28093896 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) and topical administration of tranexamic acid (TXA) (15 mg/kg i.v. and 1.0 g topically)
Number of subjects: 100
Study 28093896 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline both i.v. and topically)
Number of subjects: 100
Study 24635496 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (400 μg) 4 hourly
Number of subjects: 90
Study 24635496 — intervention group
Group type: COMPARATOR
Intervention: Intracervical Foley catheter
Number of subjects: 90
Study 24635496 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of intracervical Foley catheter and intravaginal misoprostol (400 μg) 4 hourly
Number of subjects: 90
Study 23873542 — intervention group
Group type: EXPERIMENTAL
Intervention: Cool perches
Number of subjects: 1152
Study 23873542 — intervention group
Group type: COMPARATOR
Intervention: High stocking density
Number of subjects: 1152
Study 21572318 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 208
Study 21572318 — intervention group
Group type: COMPARATOR
Intervention: Ambu AuraOnce
Number of subjects: 208
Study 19486375 — intervention group
Group type: EXPERIMENTAL
Intervention: PALS after treatment modelling intervention
Number of subjects: 53
Study 19486375 — intervention group
Group type: COMPARATOR
Intervention: Control group (motivational rewards only)
Number of subjects: 53
Study 16479769 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingualized occlusion (LO)
Number of subjects: 28
Study 16479769 — intervention group
Group type: COMPARATOR
Intervention: Bilateral balanced occlusion (BBO)
Number of subjects: 28
Study 16479769 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LO and BBO
Number of subjects: 28
Study 12635944 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyalgia rheumatica (PMR) patients
Number of subjects: 315
Study 12635944 — intervention group
Group type: COMPARATOR
Intervention: Matched population controls
Number of subjects: 315
Study 12635944 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality rate ratio (MRR) for PMR vs controls
Number of subjects: 315
Study 12635944 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality from coronary heart disease or stroke
Number of subjects: 315
Study 12635944 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality from cancer
Number of subjects: 315
Study 12635944 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality from other causes
Number of subjects: 315
Study 10632830 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational intervention simulating informed consent presentation about CRC screening (relative risk reduction)
Number of subjects: 399
Study 10632830 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational intervention simulating informed consent presentation about CRC screening (absolute risk reduction)
Number of subjects: 399
Study 10632830 — intervention group
Group type: COMPARATOR
Intervention: Control message briefly describing CRC screening methods
Number of subjects: 399
Study 10632830 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational intervention simulating informed consent presentation about CRC screening (general)
Number of subjects: 399
Study 8924192 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline with IPT
Number of subjects: 72
Study 8924192 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline with medication clinic (no IPT)
Number of subjects: 72
Study 8924192 — intervention group
Group type: COMPARATOR
Intervention: Placebo with IPT
Number of subjects: 72
Study 8924192 — intervention group
Group type: COMPARATOR
Intervention: Placebo with medication clinic
Number of subjects: 72
Study 1382793 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral incision of the prostate (TUIP)
Number of subjects: 220
Study 1382793 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection (TURP)
Number of subjects: 220
Study 3877214 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell Saver
Number of subjects: 27
Study 3877214 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafilter
Number of subjects: 27
Study 3877214 — intervention group
Group type: COMPARATOR
Intervention: Retrospective Control
Number of subjects: 27
Study 29681145 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of risk of drinking alcohol frequently
Number of subjects: 3365
Study 29681145 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of risk of getting drunk
Number of subjects: 3365
Study 29681145 — intervention group
Group type: EXPERIMENTAL
Intervention: Males, 12 years or younger
Number of subjects: 3365
Study 29681145 — intervention group
Group type: EXPERIMENTAL
Intervention: Good relationship with mothers
Number of subjects: 3365
Study 28002714 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (32 to 34°C for 24 hours)
Number of subjects: 270
Study 28002714 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone (Control)
Number of subjects: 270
Study 24628736 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil ODT 10 mg
Number of subjects: 127
Study 24628736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127